ProCE Banner Activity

CE / CME

Expert Think Tank on Applying the Latest Data to Individualize Treatment in Prostate Cancer

Text Module

Experts on prostate cancer discuss applying the latest data on prostate cancer considering recent therapy and imaging approvals.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 16, 2023

Expiration: August 15, 2024

Share

Faculty

Alicia Morgans

Alicia Morgans, MD, MPH

Associate ProfessorDana-Farber Cancer InstituteBoston, Massachusetts

Tanya B. Dorff

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Michael Schweizer

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

David VanderWeele

David VanderWeele, MD, PhD

Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC., in partnership with ZERO Prostate Cancer

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Lilly, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Merck Sharp & Dohme Corp.

Novartis

Partners

ZERO Prostate Cancer

ProCE Banner

Target Audience

This educational program is intended for urologists, oncologists, nurse practitioners, and other healthcare professionals who care for patients with prostate cancer. This educational program is also intended to reach patients with prostate cancer and their caregivers.

Program Learning Goal

The goal of this activity is to educate urologists, oncologists, nurse practitioners, nurses, pharmacists, other healthcare professionals, and patients and caregivers about recent developments in the treatment of prostate cancer to optimally individualize equitable care for every patient.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate new and emerging data for the treatment of advanced or metastatic prostate cancer into current clinical practice to optimize clinical outcomes

  • Plan individualized therapeutic strategies for metastatic prostate cancer, considering all available agents, optimal agent sequence, available clinical data, expert recommendations, and patient goals and preferences

  • Counsel patients with metastatic prostate cancer and their caregivers on available treatment options, considering differences in administration, safety profiles, efficacy, and individual patient comorbidities and goals

  • Evaluate strategies to promote health equity in the care of patients with prostate cancer, including access to care, treatment, and clinical outcomes

  • Refer appropriate patients with prostate cancer to ongoing clinical trials investigating novel therapies throughout the disease continuum

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Alicia Morgans, MD, MPH

Associate ProfessorDana-Farber Cancer InstituteBoston, Massachusetts

Alicia K. Morgans, MD, MPH: consultant/advisor/speaker: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Foundation Medicine, Exelixis, Janssen, Lantheus, Myovant, Myriad, Novartis, Pfizer, Sanofi, SeaGen, Telix.

Primary Author

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Tanya B. Dorff, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Janssen, Sanofi.

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus.

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Michael T. Schweizer, MD: consultant/advisor/speaker: AstraZeneca, PharmaIn, Sanofi; researcher (paid to institution): Ambrx, AstraZeneca, Bristol Myers Squibb, Epigenetics, Epigenetix, Hoffman-La Roche, Immunomedics, Incyte, Janssen, Merck, Novartis, Pfizer, SignalOne Bio, Tmunity, Xencoer, Zenith.

David VanderWeele, MD, PhD

Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois

David VanderWeele, MD, PhD: consultant/advisor/speaker: Astellas, AstraZeneca Bayer, Exelixis, Janssen, Myovant; researcher (paid to institution): AstraZeneca, Bayer, Genentech.

The planners and content peer reviewers from Clinical Care Options, LLC and ZERO Prostate Cancer do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 16, 2023, through August 15, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is  1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-204-H01-P 
Type of Activity: Application 

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.